BioSniper
Phase 1 Start~month

Phase 1 Start: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study to Investigate the S

July 7, 2026
Company
BIOGEN INC. (BIIB)
Indication
Healthy Volunteer

Other upcoming events for BIIB

Phase 3 ReadoutPhase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an
Jun 1, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrop
Sep 24, 2027
Phase 3 ReadoutPhase 3 Topline: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Mu
Dec 14, 2027
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartam
Mar 29, 2029
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Neph
Jun 5, 2029

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
BIIB OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle